Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0167 in Healthy Participants
NCT07722299Phase 1Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of SAL0167 in hyperlipidemia (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Adverse Events at 50 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
SAL0167
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07722299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722299.